|
极重型新生儿高胆红素血症治疗1例
|
Abstract:
随着人们对新生儿黄疸认识的深入及医疗机构对新生儿高胆红素血症的规范管理,极重型新生儿高胆红素血症目前在临床并不常见,该病在诊断上并不困难,但发现时已是极重型高胆红素血症,易发展为胆红素脑病,造成神经系统损伤,严重影响新生儿今后生长发育及健康,因此治疗上需光疗联合其他多种治疗措施,尽快将胆红素降低至安全阈值以下,减少胆红素脑病的发生。本病例患儿胆红素水平达到极重型,经过光疗,静脉输注白蛋白、免疫球蛋白、补液等治疗措施,早期积极干预,迅速降低了患儿胆红素水平,避免了胆红素脑病的发生,预后良好。
With the deepening of people’s understanding of neonatal jaundice and the standardized management of neonatal hyperbilirubinemia by medical institutions, extremely severe neonatal hyperbilirubinemia is not common in clinical practice. The disease is not difficult to diagnose, but when it is discovered, it is already extremely severe hyperbilirubinemia, which is prone to develop into bilirubin encephalopathy and cause nervous system damage. Therefore, phototherapy combined with other multiple treatment measures is required for treatment to reduce bilirubin to below the safe threshold as soon as possible and reduce the occurrence of bilirubin encephalopathy. The bilirubin level of the child in this case reached an extremely severe level. After phototherapy, intravenous infusion of albumin, immunoglobulin, fluid infusion and other treatment measures, early active intervention quickly reduced the bilirubin level of the child, avoided the occurrence of bilirubin encephalopathy, and had a good prognosis.
[1] | 李茂军, 唐彬秩, 吴青, 等. 新生儿高胆红素血症的管理-美国儿科学会及多国临床管理指南解读[J]. 中华实用儿科临床杂志, 2023, 38(3): 161-168. |
[2] | 中华医学会儿科学分会新生儿学组, 《中华儿科杂志》编辑委员会. 新生儿高胆红素血症诊断和治疗专家共识[J]. 中华儿科杂志, 2014, 52(10): 745-748. |
[3] | American Academy of Pediatrics Subcommittee on Hyperbilirubinemia (2004) Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics, 114, 297-316. https://doi.org/10.1542/peds.114.1.297 |
[4] | 霍怡萱, 彭程, 侯新琳, 等. 美国儿科学会新生儿高胆红素血症临床指南修订: 胎龄35周及以上新生儿高胆红素血症的管理[J]. 中华新生儿科杂志(中英文), 2023, 38(9): 513-524. |
[5] | 李楠, 栗昊. 益生菌和维生素B2联合蓝光治疗新生儿高胆红素血症的效果及对患儿机体免疫功能的影响[J]. 当代医学, 2022, 28(5): 124-126. |
[6] | 王晓英, 顾益琴, 许丽娅. 地衣芽孢杆菌联合蓝光照射对新生儿高胆红素血症患儿黄疸消退时间及血清胆红素水平的影响[J]. 妇儿健康导刊, 2022, 1(7): 56-59. |
[7] | Kemper, A.R., Newman, T.B., Slaughter, J.L., Maisels, M.J., Watchko, J.F., Downs, S.M., et al. (2022) Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics, 150, e2022058859. https://doi.org/10.1542/peds.2022-058859 |
[8] | 高璐, 芦起. 新生儿光疗不良反应研究进展[J]. 中华新生儿科杂志, 2021, 36(2): 75-78. |
[9] | 任念. 新生儿黄疸规范化用药指导专家建议[J]. 中国医药导报, 2019, 16(27): 105-110. |
[10] | Dash, N., Kumar, P., Sundaram, V. and Attri, S.V. (2015) Pre-Exchange Albumin Administration in Neonates with Hyperbilirubinemia: A Randomized Controlled Trial. Indian Pediatrics, 52, 763-767. https://doi.org/10.1007/s13312-015-0713-z |
[11] | Lieberman, L., Lopriore, E., Baker, J.M., Bercovitz, R.S., Christensen, R.D., Crighton, G., et al. (2022) International Guidelines Regarding the Role of IVIG in the Management of Rh-and Abo-Mediated Haemolytic Disease of the Newborn. British Journal of Haematology, 198, 183-195. https://doi.org/10.1111/bjh.18170 |